Table 3. Treatment Thresholds of 2021 European-SCORE2 Corresponding to Treatment Thresholds of US-PCE, UK-QRISK3, and European-SCORE1 in Individuals Aged 40 to 69 Years.
| Cut point (10-y risk) | Statin eligibility in the population, % | Performance for European-SCORE2–defined ASCVD eventsa | ||
|---|---|---|---|---|
| Sensitivity, % | Specificity, % | |||
| European-SCORE2 vs US-PCE, % | ||||
| SCORE2 | PCE | |||
| 10.0 | 20.7 | 5 | 12 | 95 |
| 9.8 | 20.0 | 6 | 14 | 93 |
| 5.1 | 7.5 | 32 | 57 | 69 |
| 3.9 | 5.0 | 44 | 71 | 56 |
| European-SCORE2 vs UK-QRISK3, % | ||||
| SCORE2 | QRISK3 | |||
| 10.0 | 20.2 | 5 | 12 | 95 |
| 5.8 | 10.0 | 26 | 50 | 75 |
| European-SCORE2 vs European-SCORE1, % | ||||
| SCORE2 | SCORE1 | |||
| 11.3 | 10.0 | 3 | 9 | 97 |
| 7.0 | 5.0 | 15 | 32 | 86 |
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; PCE, pooled cohort equations; SCORE, Systematic Coronary Risk Evaluation.
a
European-SCORE2 end point of fatal ASCVD, nonfatal myocardial infarction, and stroke.